Back to Newsroom
Back to Newsroom

Chembio Diagnostics, Inc. to Host Fourth Quarter Earnings Webcast Live on Thursday, March 6, 2014

Wednesday, 05 March 2014 09:30 AM

Chembio Diagnostics, Inc.

Topic:

MEDFORD, NY  / ACCESSWIRE / March 5, 2014 / Chembio Diagnostics, Inc. (CEMI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Thursday, March 6, 2014 at 10:00 AM Eastern Time.

To participate in this event, dial 877-407-0778 domestically, or 201-689-8565 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at http://www.investorcalendar.com/IC/CEPage.asp?ID=172309.

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=172309 or http://www.investorcalendar.com/, as well as via the Chembio Diagnostics web site (http://www.chembio.com/).

About Chembio Diagnostics

Chembio Diagnostics develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $10 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP®. Headquartered in Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13.485. For additional information please visit http://www.chembio.com/.

 

 

SOURCE: InvestorCalendar

Topic:
Back to newsroom
Back to Newsroom
Share by: